ArticleBlood cancer discovery2020
Monosomic loss of MIR15A/MIR16-1 is a driver of multiple myeloma proliferation and disease progression.
Open access · greenAbstract read
In one paragraph
Article in Blood cancer discovery, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
2.8field-weighted citation impact, top 8% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 39 citations in OpenAlex.
- Prognostic impact of monosomy 13 and deletion of 13q in multiple myeloma patients undergoing upfront autologous transplantation.British journal of haematology · 2026Article
- Distinct immunophenotypic profiles of circulating tumor plasma cells in MGUS and smoldering multiple myeloma.International journal of hematology · 2026Article
- Integrated analysis of miR-15a-5p, miR-20a-5p, and miR-33b-3p identifies EGR2-associated biomarkers in multiple myeloma.BMC cancer · 2026Article
- RNA-Based Therapeutic Strategies in Multiple Myeloma: From Molecular Targets to Delivery and Clinical Translation.International journal of molecular sciences · 2026Review
- A Phase I Clinical Study and In Vivo Findings with PT-112, a Novel Immunogenic Cell Death-Inducing Small Molecule, in Relapsed or Refractory Multiple Myeloma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Article
- B-cell-specificBlood neoplasia · 2025Article
- Immunocompetent mouse models of multiple myeloma.Seminars in hematology · 2025Review
- A Role for Germline Variants in Multiple Myeloma?Blood cancer discovery · 2024Article
- Long Noncoding RNAs Expressed in Mouse Pituitary Development and Mature Hormone-Producing Cells.Endocrinology · 2024Article
- Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes.Nature genetics · 2024Observational
- The genomic landscape of Vk*MYC myeloma highlights shared pathways of transformation between mice and humans.Nature communications · 2024Article
- Genomic Classification and Individualized Prognosis in Multiple Myeloma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024Article
- Immunocompetent Mouse Models of Multiple Myeloma: Therapeutic Implications.Hematology/oncology clinics of North America · 2024Review
- In-depth cytogenetic and immunohistochemical analysis in a real world cohort - reconsidering the role of primary and secondary aberrations in multiple myeloma.Haematologica · 2024Article
- The Genetic and Molecular Drivers of Multiple Myeloma: Current Insights, Clinical Implications, and the Path Forward.Pharmacogenomics and personalized medicine · 2024Review
- Complete miRNA-15/16 loss in mice promotes hematopoietic progenitor expansion and a myeloid-biased hyperproliferative state.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- Molecular characterization stratifies VQ myeloma cells into two clusters with distinct risk signatures and drug responses.Oncogene · 2023Article
- Article
- The Landscape of Nucleic-Acid-Based Aptamers for Treatment of Hematologic Malignancies: Challenges and Future Directions.Bioengineering (Basel, Switzerland) · 2022Review
- Review of Multiple Myeloma Genetics including Effects on Prognosis, Response to Treatment, and Diagnostic Workup.Life (Basel, Switzerland) · 2022Review
Corrections and comments
- Commented on by
Authors and funding
12 authors at 3 institutions in 1 country.
Marta ChesiDivision of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, Arizona. chesi.marta@mayo.edu.ORCID 0000-0002-4024-8225
Caleb K SteinDivision of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, Arizona.
Victoria M GarbittDivision of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, Arizona.
Meaghen E SharikDivision of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, Arizona.
Yan W AsmannDivision of Health Science Research, Mayo Clinic, Jacksonville, Florida.
Matteo BergsagelDivision of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, Arizona.ORCID 0000-0003-1523-7388
Daniel L RiggsDivision of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, Arizona.
Seth J WelshDivision of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, Arizona.
Erin W MeermeierDivision of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, Arizona.
Shaji K KumarDivision of Hematology and Medical Oncology, Mayo Clinic, Rochester, Minnesota.
Esteban BraggioDivision of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, Arizona.
P Leif BergsagelDivision of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, Arizona.ORCID 0000-0003-1523-7388
Mayo Clinic in Arizona · USJacksonville College · USMayo Clinic · US
Funding
Project 4: Targeting Resistance to T-Cell Directed Therapy in Multiple MyelomaP50CA186781 · NCI · MAYO CLINIC ARIZONA · PI Peter Leif Bergsagel · 2015 to 2026
$25.5MProject 3 - Modeling Proteasome Inhibitor Response and Resistance in Cell Lines and Patient Samples with Single Cell Analysis of SubpopulationsU54CA224018 · NCI · MAYO CLINIC ARIZONA · PI BERGSAGEL, PETER LEIF · 2017 to 2021
$6.0MPrevalence and Progression of Monoclonal GammopathiesR01CA107476 · NCI · MAYO CLINIC ROCHESTER · PI KUMAR, SHAJI KUNNATHU, RAJKUMAR, S VINCENT · 2004 to 2018
$4.6MOnset and biomarkers for progression of monoclonal gammopathiesR01CA168762 · NCI · MAYO CLINIC ROCHESTER · PI KUMAR, SHAJI KUNNATHU, RAJKUMAR, S VINCENT · 2012 to 2024
$3.2MCredentialing a Genetically Engineered Clinically-Relevant Mouse Model of Multiple MyelomaR01CA234181 · NCI · MAYO CLINIC ARIZONA · PI CHESI, MARTA · 2019 to 2023
$1.9MPQD2 Rational Combination of Standard Agents and Immunotherapy to Treat MyelomaR01CA190045 · NCI · MAYO CLINIC ARIZONA · PI CHESI, MARTA · 2014 to 2017
$1.4MNCI NIH HHS P50 CA186781NCI NIH HHS R01 CA107476NCI NIH HHS R01 CA168762NCI NIH HHS R01 CA190045NCI NIH HHS R01 CA234181NCI NIH HHS U54 CA224018
Abstract
The most common genetic abnormality in multiple myeloma (MM) is the deletion of chromosome 13, seen in almost half of newly diagnosed patients. Unlike chronic lymphocytic leukemia, where a recurrent minimally deleted region including
Indexed as
Leukemia, Lymphocytic, Chronic, B-CellMicroRNAsMonoclonal Gammopathy of Undetermined SignificanceMultiple MyelomaAnimalsCell ProliferationDisease ProgressionHumansMiceMicroRNAsMIRN15 microRNA, humanMIRN16 microRNA, human
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.